Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
about
Ocular toxicity from systemically administered xenobiotics.Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.Ocular side effects of biological agents in oncology: what should the clinician be aware of?
P2860
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
@ast
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
@en
type
label
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
@ast
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
@en
prefLabel
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
@ast
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
@en
P2860
P1476
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer
@en
P2093
Jin Hak Lee
Won Ryang Wee
P2860
P304
P356
10.3341/KJO.2011.25.5.355
P577
2011-09-20T00:00:00Z